{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(1)"],"submitter":["Presa M"],"pubmed_abstract":["<h4>Background</h4>Multiple Sulfatase Deficiency (MSD) is an ultra-rare autosomal recessive disorder characterized by deficient enzymatic activity of all known sulfatases. MSD patients frequently carry two loss of function mutations in the SUMF1 gene, encoding a formylglycine-generating enzyme (FGE) that activates 17 different sulfatases. MSD patients show common features of other lysosomal diseases like mucopolysaccharidosis and metachromatic leukodystrophy, including neurologic impairments, developmental delay, and visceromegaly. There are currently no approved therapies for MSD patients. Hematopoietic stem cell transplant (HSCT) has been applied with success in the treatment of certain lysosomal diseases. In HSCT, donor-derived myeloid cells are a continuous source of active sulfatase e"],"journal":["Communications medicine"],"pagination":["215"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11502872"],"repository":["biostudies-literature"],"pubmed_title":["Bone marrow transplantation increases sulfatase activity in somatic tissues in a multiple sulfatase deficiency mouse model."],"pmcid":["PMC11502872"],"pubmed_authors":["Pham V","Billings T","Presa M","Schlotawa L","Lutz C","Piec PA","Lund T","Coombs H","Ryan J","Ahrens-Nicklas RC","Ray S"],"additional_accession":[]},"is_claimable":false,"name":"Bone marrow transplantation increases sulfatase activity in somatic tissues in a multiple sulfatase deficiency mouse model.","description":"<h4>Background</h4>Multiple Sulfatase Deficiency (MSD) is an ultra-rare autosomal recessive disorder characterized by deficient enzymatic activity of all known sulfatases. MSD patients frequently carry two loss of function mutations in the SUMF1 gene, encoding a formylglycine-generating enzyme (FGE) that activates 17 different sulfatases. MSD patients show common features of other lysosomal diseases like mucopolysaccharidosis and metachromatic leukodystrophy, including neurologic impairments, developmental delay, and visceromegaly. There are currently no approved therapies for MSD patients. Hematopoietic stem cell transplant (HSCT) has been applied with success in the treatment of certain lysosomal diseases. In HSCT, donor-derived myeloid cells are a continuous source of active sulfatase e","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2025-04-26T00:15:37.988Z","creation":"2025-04-06T09:39:46.991Z"},"accession":"S-EPMC11502872","cross_references":{"pubmed":["39448727"],"doi":["10.1038/s43856-024-00648-y"]}}